title: Antiphopholipid antibodies and functional activated protein C resistance in patients with breast cancer during anthracycline-based chemotherapy administered through an intravenous port-catheter device.
authors.affiliation: 1Department of Obstetrics and Gynecology, City Hospital of Aschaffenburg, Aschaffenburg, Germany.
authors.forename: A A
authors.initials: AA
authors.lastname: Soliman
authors.forename: R
authors.initials: R
authors.lastname: Csorba
authors.forename: A
authors.initials: A
authors.lastname: Ullrich
authors.forename: P
authors.initials: P
authors.lastname: Tsikouras
authors.forename: W
authors.initials: W
authors.lastname: Rath
authors.forename: G-F
authors.initials: GF
authors.lastname: von Tempelhoff
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000378:metabolism*; D061605:Administration, Intravenous; D018943:Anthracyclines / Q000008:administration & dosage / Q000009:adverse effects; D017152:Antibodies, Antiphospholipid / Q000097:blood / Q000378:metabolism*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000276:immunology*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008875:Middle Aged
chemical_list: D018943:Anthracyclines; D017152:Antibodies, Antiphospholipid